• Bookmark this Page
  • Print this Page

Doctor Louis Potters

Louis Potters, MD, FACR, Chairman, Department of Radiation Medicine

Louis Potters, MD, FACR, an internationally renowned expert in prostate cancer treatment and research, was appointed Chairman of Radiation Medicine at North Shore University Hospital and LIJ Medical Center in 2007.

Board-certified in internal medicine and radiation oncology, Dr. Potters comes to North Shore-LIJ Health System from South Nassau Communities Hospital in Oceanside, where he was Associate Director of Radiation Oncology and Medical Director of the New York Prostate Institute. Since 2006, he has also been an attending physician at Southside Hospital in Bay Shore, which is also a member of the North Shore-LIJ Health System. Before joining South Nassau, Dr. Potters was an Associate Professor of Radiation Oncology at Memorial Sloan Kettering Cancer Center. In 1992, Dr. Potters became the first physician to offer prostate brachytherapy on Long Island during his tenure as an attending physician in radiation oncology at North Shore University Hospital.

Dr. Potters is a member of the Board of Directors and Chair of the Health Policy Council for the American Society of Therapeutic Radiology, the largest international association of radiation oncologists. He also sits on or chairs numerous committees and task forces of various medical societies, and has lectured and written extensively on prostate cancer and radiation oncology.

Dr. Potters has written over 60 peer reviewed articles on radiation oncology and has over 100 accepted abstracts. He is on the editorial board of three leading scientific journals, and peer reviews manuscripts for eight other periodicals. Dr. Potters lectures and teaches throughout the country and world.

Dr. Potters received his medical degree from the University of Medicine and Dentistry of New Jersey in Newark, New Jersey, and a Bachelor of Science degree from Emory University in Atlanta, Georgia.

Louis Potters, MD FACR
Department of Radiation Medicine
North Shore-LIJ Health System

Emory University
UMDNJ-New Jersey Medical School
SUNY-Downstate Medical Center

Board Certification: Internal Medicine, Radiation Oncology

Printable version of Dr. Potters' biography

Dr. Potters' Publications

  1. Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Fearn PA, Kattan MW, Stock RG.Customized Dose Prescription for Permanent Prostate Brachytherapy: Insights from a Multicenter Analysis of Dosimetry Outcomes. Int J Radiat Oncol Biol Phys. 2007 Aug 3; [Epub ahead of print] PMID: 17689026 [PubMed - as supplied by publisher]
  2. Potters L.
    The art of radiation oncology? Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):966-7. No abstract available. PMID: 17637388 [PubMed - indexed for MEDLINE]
  3. Potters L, Timmerman R, Larson D.
    Stereotactic body radiation therapy. J Am Coll Radiol. 2005 Aug;2(8):676-80. Review. PMID: 17411904 [PubMed - indexed for MEDLINE]
  4. Frank SJ, Grimm PD, Sylvester JE, Merrick GS, Davis BJ, Zietman A, Moran BJ, Beyer DC, Roach M 3rd, Clarke DH, Stock RG, Robert Lee W, Michalski JM, Wallner KE, Hurwitz M, Potters L, Kuban DA, Prestidge BR, Vera R, Hathaway S, Blasko JC.
    Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Brachytherapy. 2007 Jan-Mar;6(1):2-8. PMID: 17284379 [PubMed - indexed for MEDLINE]
  5. Acher PL, Popert R, Morris SL, Potters L, Austin-Smith SL, Johnson UH, Nichol JE, Beaney RP.
    Dynamic dose-feedback prostate brachytherapy in patients with large prostates and/or planned transurethral surgery before implantation. BJU Int. 2007 May;99(5):1066-71. Epub 2007 Jan 16. PMID: 17233801 [PubMed - indexed for MEDLINE]
  6. Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM.
    Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):327-33. Epub 2006 Nov 2. PMID: 17084558 [PubMed - indexed for MEDLINE]
  7. Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, Horwitz EM.
    Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1487-93. Epub 2006 Jun 5. PMID: 16750326 [PubMed - indexed for MEDLINE]
  8. Williams SG, Pickles T, Kestin L, Potters L, Fearn P, Smith R, Pratt G.
    A multicenter study demonstrating discordant results from electronic prostate-specific antigen biochemical failure calculation systems. Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1494-500. Epub 2006 May 26. PMID: 16730132 [PubMed - indexed for MEDLINE]
  9. Potters L, Calugaru E, Jassal A, Presser J.
    Is there a role for postimplant dosimetry after real-time dynamic permanent prostate brachytherapy? Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):1014-9. Epub 2006 May 6. PMID: 16682144 [PubMed - indexed for MEDLINE]
  10. Acher PL, Morris SL, Popert RJ, Perry MJ, Potters L, Beaney RP.
    Permanent prostate brachytherapy: a century of technical evolution. Prostate Cancer Prostatic Dis. 2006;9(3):215-20. Epub 2006 May 9. Review. PMID: 16683013 [PubMed - indexed for MEDLINE]
  11. Dillehay GL, Ellerbroek NA, Balon H, Brill DR, Grigsby PW, Macklis RM, Mauch PM, Mian TA, Potters L, Silberstein EB, Williams TR, Wong JC, Gaspar LE; American Society for Therapeutic Radiology and Oncology.
    Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources. Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1299-307. Epub 2006 Feb 10. No abstract available. PMID: 16472933 [PubMed - indexed for MEDLINE]
  12. Crook JM, Potters L, Stock RG, Zelefsky MJ.
    Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk. Brachytherapy. 2005;4(3):186-94. PMID: 16182218 [PubMed - indexed for MEDLINE]
  13. Potters L, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, Mullen E.
    12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2005 May;173(5):1562-6. PMID: 15821486 [PubMed - indexed for MEDLINE]
  14. Potters L, Steinberg M, Rose C, Timmerman R, Ryu S, Hevezi JM, Welsh J, Mehta M, Larson DA, Janjan NA; American Society for Therapeutic Radiology and Oncology; American College of Radiology.
    American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1026-32. No abstract available. PMID: 15519771 [PubMed - indexed for MEDLINE]
  15. Potters L, Klein EA, Kattan MW, Reddy CA, Ciezki JP, Reuther AM, Kupelian PA.
    Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol. 2004 Apr;71(1):29-33. PMID: 15066293 [PubMed - indexed for MEDLINE]
  16. Potters L, Fearn P, Kattan MW.
    External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer. Brachytherapy. 2002;1(1):36-41. PMID: 15062185 [PubMed - indexed for MEDLINE]
  17. Potters L, Huang D, Fearn P, Kattan MW.
    The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy. Brachytherapy. 2003;2(1):26-31. PMID: 15062160 [PubMed - indexed for MEDLINE]
  18. Potters L, Calguaru E, Thornton KB, Jackson T, Huang D.
    Toward a dynamic real-time intraoperative permanent prostate brachytherapy methodology. Brachytherapy. 2003;2(3):172-80. PMID: 15062140 [PubMed - indexed for MEDLINE]
  19. Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA.
    Radical prostatectomy, external beam radiotherapy or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):25-33. PMID: 14697417 [PubMed - indexed for MEDLINE]
  20. Potters L, Huang D, Calugaru E, Fearn P, Lee L, Kattan MW.
    Importance of implant dosimetry for patients undergoing prostate brachytherapy. Urology. 2003 Dec;62(6):1073-7. PMID: 14665358 [PubMed - indexed for MEDLINE]
  21. Yamada Y, Potters L, Zaider M, Cohen G, Venkatraman E, Zelefsky MJ.
    Impact of intraoperative edema during transperineal permanent prostate brachytherapy on computer-optimized and preimplant planning techniques. Am J Clin Oncol. 2003 Oct;26(5):e130-5. PMID: 14528087 [PubMed - indexed for MEDLINE]
  22. Potters L, Kattan MW, Fearn P.
    A chronological database to support outcomes research in prostate cancer. Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1252-8. PMID: 12873669 [PubMed - indexed for MEDLINE]
  23. Potters L, Purrazzella R, Brustein S, Fearn P, Huang D, Leibel SA, Kattan MW.
    The prognostic significance of Gleason Grade in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):749-54. PMID: 12788181 [PubMed - indexed for MEDLINE]
  24. Potters L, Steinberg M, Wallner P, Hevezi J.
    How one defines intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):609-10. No abstract available. PMID: 12788164 [PubMed - indexed for MEDLINE]
  25. Potters L, Purrazzella R, Brustein S, Fearn P, Leibel SA, Kattan MW.
    A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma. Cancer. 2002 Oct 1;95(7):1451-6. PMID: 12237913 [PubMed - indexed for MEDLINE]
  26. Lee LN, Barnswell C, Torre T, Fearn P, Kattan M, Potters L.
    Prognostic significance of race on biochemical control in patients with localized prostate cancer treated with permanent brachytherapy: multivariate and matched-pair analyses. Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):282-9. PMID: 12023131 [PubMed - indexed for MEDLINE]
  27. Potters L.
    Nomograms for clinically localized prostate cancer. Part II: radiation therapy. Semin Urol Oncol. 2002 May;20(2):131-9. Review. PMID: 12012299 [PubMed - indexed for MEDLINE


Back to Top